Skip to content
Peptigraph home

Rybelsus vs Ozempic: What the Research Shows

Rybelsus and Ozempic side by side: what they are, how they are regulated and what is still unknown.

Medically reviewed by Juan Pablo Frías, MD · · DisclosureUpdated
Brand of Semaglutide (GLP-1 agonist)FDA approved (Ozempic, Wegovy, Rybelsus)RybelsusNovo Nordisk's oral semaglutide tablet brand, FDA-labeled as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes.[10]GLP-1 & metabolic
Brand of Semaglutide (GLP-1 agonist)FDA approved (Ozempic, Wegovy, Rybelsus)OzempicNovo Nordisk's injectable semaglutide brand, FDA-labeled as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes.[5]GLP-1 & metabolic
Quick verdict

Where the research points

Summary of studies, not a recommendation

Consider Rybelsus if…

  • you prefer a daily tablet to a weekly injection: Rybelsus starts at 3 mg orally once daily (a starting dose not effective for glycemic control)[10]
  • you want an oral semaglutide: Rybelsus tablets are indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes[10]

Consider Ozempic if…

  • you prefer a weekly injection: Ozempic starts at 0.25 mg injected once weekly for 4 weeks[5]
  • you want the label with a kidney indication: Ozempic is indicated to reduce sustained eGFR decline, end-stage kidney disease and cardiovascular death in type 2 diabetes with chronic kidney disease[5]
Status labels come from public FDA and WADA records; see the sources below.
Side by side

Spec comparison

Showing all 11 fields. Highlighted rows differ.

FieldRybelsusOzempic
ClassBrand of Semaglutide (GLP-1 agonist)Brand of Semaglutide (GLP-1 agonist)
Also calledBrand name of SemaglutideBrand name of Semaglutide
CategoryGLP-1 & metabolicGLP-1 & metabolic
FDA statusFDA approved (Ozempic, Wegovy, Rybelsus)FDA approved (Ozempic, Wegovy, Rybelsus)
PCAC vote, Jul 2026Not on the Jul 2026 agendaNot on the Jul 2026 agenda
WADANot on the WADA Prohibited ListGLP-1 and GIP agonists are not named anywhere on the 2026 list. This one is an approved medicine, so the catch-all S0 (which only covers drugs with no approval anywhere) does not apply to it.Not on the WADA Prohibited ListGLP-1 and GIP agonists are not named anywhere on the 2026 list. This one is an approved medicine, so the catch-all S0 (which only covers drugs with no approval anywhere) does not apply to it.
Half-lifeapproximately 1 weeksubcutaneous · FDA label (Ozempic)approximately 1 weeksubcutaneous · FDA label (Ozempic)
Evidence strengthHuman RCT evidence, 4 of 4Strongest: Lancet 2026, PMID 41865758Human RCT evidence, 4 of 4Strongest: Lancet 2026, PMID 41865758
Human studies we summarised23 human (19 randomized or controlled) of 27 summarised23 human (19 randomized or controlled) of 27 summarised
Typical study doses
Named in FDA warning letters, 2026Yes (24 Aug 2026; 31 Mar 2026)Yes (24 Aug 2026; 31 Mar 2026)

Bracketed values are pending a sourced figure. Legal data reflects the regulatory events in our tracker.

Sources

  1. 1FDA warning letters to five research-peptide sellersFDA warning letter (NuScience Peptides; 1 of 5) · 2026fda.govAccessed 2 Oct 2026
  2. 2FDA proposes excluding semaglutide, tirzepatide and liraglutide from the 503B bulks listFDA · 2026fda.govAccessed 2 Oct 2026
  3. 3Seven FDA warning letters to online sellers of GLP-1 productsFDA warning letter (Gram Peptides; 1 of 7) · 2026fda.govAccessed 2 Oct 2026
  4. 4World Anti-Doping Code International Standard Prohibited List 2026World Anti-Doping Agency · 2026wada-ama.orgAccessed 2 Oct 2026
  5. 5These highlights do not include all the information needed to use OZEMPIC ® safely and effectively. See full prescribing information for OZEMPIC. OZEMPIC (semaglutide) injection, for subcutaneous use FDA label (Ozempic), DailyMed · current labeldailymed.nlm.nih.govAccessed 2 Oct 2026
  6. 6Efficacy and safety of oral semaglutide 14 mg (flexible dose) in early-stage symptomatic Alzheimer's disease (evoke and evoke+): two phase 3, randomised, placebo-controlled trials.Lancet (London, England) · 2026PMID 41865758Accessed 2 Oct 2026
  7. 7Phase 3 Trial of Semaglutide in Metabolic Dysfunction-Associated Steatohepatitis.The New England journal of medicine · 2025PMID 40305708Accessed 2 Oct 2026
  8. 8Oral Semaglutide at a Dose of 25 mg in Adults with Overweight or Obesity.The New England journal of medicine · 2025PMID 40934115Accessed 2 Oct 2026
  9. 9PubMed search: (Ozempic[tiab]) AND (Rybelsus[tiab])PubMed · 2026pubmed.ncbi.nlm.nih.govAccessed 2 Oct 2026
  10. 10RYBELSUS and OZEMPIC tablets prescribing information (FDA label)FDA label, DailyMed · current labeldailymed.nlm.nih.govAccessed 2 Oct 2026

Found an error? Report a correction.